Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

264 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The use of granulocyte colony-stimulating factor to shorten the interval between cycles of mitomycin C, vindesine, and cisplatin chemotherapy in non-small-cell lung cancer.
Takada M, Fukuoka M, Ariyoshi Y, Furuse K, Niitani H, Ota K, Motomiya M, Hasegawa K, Tominaga K, Kuriyama T, et al. Takada M, et al. Among authors: furuse k. Cancer Chemother Pharmacol. 1992;31(3):182-6. doi: 10.1007/BF00685545. Cancer Chemother Pharmacol. 1992. PMID: 1281446 Clinical Trial.
Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
Kudoh S, Sawa T, Kurihara N, Furuse K, Kurita Y, Fukuoka M, Takada M, Takaku F, Ogawa M, Ariyoshi Y. Kudoh S, et al. Among authors: furuse k. Cancer Chemother Pharmacol. 1996;38 Suppl:S89-95. doi: 10.1007/s002800051046. Cancer Chemother Pharmacol. 1996. PMID: 8765425 Clinical Trial.
Phase I study of E7010.
Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Yamamoto K, et al. Among authors: furuse k. Cancer Chemother Pharmacol. 1998;42(2):127-34. doi: 10.1007/s002800050795. Cancer Chemother Pharmacol. 1998. PMID: 9654112 Clinical Trial.
264 results